The influence of genetic innate resistance and acquired immunity on drug treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania.
Enevold
A
A
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology / Q000627:therapeutic use*; D001363:Awards and Prizes; D002675:Child, Preschool; D015897:Comorbidity; D003430:Cross-Sectional Studies; D004338:Drug Combinations; D004351:Drug Resistance / Q000235:genetics; D019353:Endemic Diseases; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D005954:Glucosephosphate Dehydrogenase / Q000235:genetics; D005953:Glycogen Storage Disease Type I / Q000453:epidemiology / Q000235:genetics; D006453:Hemoglobinopathies / Q000453:epidemiology / Q000235:genetics; D006455:Hemoglobins, Abnormal / Q000032:analysis / Q000235:genetics; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics*; D007223:Infant; D016778:Malaria, Falciparum / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics*; D010963:Plasmodium falciparum / Q000187:drug effects / Q000276:immunology; D011739:Pyrimethamine / Q000494:pharmacology / Q000627:therapeutic use; D013413:Sulfadoxine / Q000494:pharmacology / Q000627:therapeutic use; D013636:Tanzania / Q000453:epidemiology; D016896:Treatment Outcome
D000962:Antimalarials; D004338:Drug Combinations; D006455:Hemoglobins, Abnormal; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D005954:Glucosephosphate Dehydrogenase; D011739:Pyrimethamine